Intergroup 0144 a phase III rectal surgical adjuvant study of pelvic radiation (XRT) plus 5-FU based chemotherapy (bolus 5-FU before and after PVI + XRT vs PVI before, during, and after XRT vs biochemically modulated bolus 5-FU and XRT): Mature outcome results and pelvic failure analysis
Stephen R. Smalley(Mayo Clinic), J Macdonald(Saint Vincent Health System), Stephen K. Williamson(The University of Kansas Cancer Center), C. Cripps(Canadian Partnership Against Cancer), Norman Estes(Southern Research Institute), James A. Martenson(Mayo Clinic), B. Fisher, J. M. Robertson(Cancer Research UK), R. Mayer(Harvard University), Jacqueline Benedetti(University of Illinois Chicago), Angela Benson(Northwestern University)
International Journal of Radiation Oncology*Biology*Physics
September 1, 2004
Cited by 6
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection
|Journal of Clinical Oncology|2012|856
PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy
|Journal of Clinical Oncology|2016|291
Phase III Trial of Fluorouracil-Based Chemotherapy Regimens Plus Radiotherapy in Postoperative Adjuvant Rectal Cancer: GI INT 0144
|Journal of Clinical Oncology|2006|167